Role of C-type natriuretic peptide signalling in maintaining cartilage and bone function

Osteoarthritis and Cartilage

Volumn 22, Issue 11, 2014, Pages 1800-1807

  Peake, N J ^a   Hobbs, A J ^b   Pingguan Murphy, B ^c   Salter, D M ^d   Berenbaum, F ^e   Chowdhury, T T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

C type natriuretic peptide; Cartilage homeostasis; Inflammation; Natriuretic peptide receptor; Osteoarthritis

Indexed keywords

AGGRECAN; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOMATERIAL; BMN 111; CHONDROITIN; COLLAGEN TYPE 2; CYCLIC GMP; CYTOKINE; GUANYLATE CYCLASE; HORMONE RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NATRIURETIC PEPTIDE RECEPTOR 2; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; PEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACHONDROPLASIA; AGING; ARTHRITIS; BONE; BONE DYSPLASIA; BONE GROWTH; CARTILAGE; CARTILAGE CELL; CELL DIFFERENTIATION; CHONDROPROTECTION; ENCHONDRAL OSSIFICATION; EXTRACELLULAR MATRIX; GENE INACTIVATION; GROWTH PLATE; GROWTH RETARDATION; HOMEOSTASIS; HUMAN; IN VITRO STUDY; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SYNTHESIS; ANIMAL; BONE DEVELOPMENT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE DEVELOPMENT; CARTILAGE; GROWTH PLATE; HOMEOSTASIS; HUMANS; NATRIURETIC PEPTIDE, C-TYPE; OSTEOGENESIS;

EID: 84908273145     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.07.018     Document Type: Review

References (64)

1. Kronenberg H.M. Developmental regulation of the growth plate. Nature 2003, 423:332-336.
2. Karsenty G., Kronenberg H.M., Settembre C. Genetic control of bone formation. Annu Rev Cell Dev Biol 2009, 25:629-648.
3. Clavell A.L., Stingo A.J., Wei C.M., Heublein D.M., Burnett J.C. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 1993, 264:R290-R295.
4. Khambata R.S., Panayiotou C.M., Hobbs A.J. Release of C-type natriuretic peptide accounts for the biological activity of endothelial-derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003, 100:1426-1431.
5. Cahill P.A., Hassid A. Clearance receptor-binding atrial natriuretic peptides inhibit mitogenesis and proliferation of rat aortic smooth muscle cells. Biochem Biophys Res Commun 1991, 179:1606-1613.
6. Ahluwalia A., Hobbs A.J. Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci 2005, 26:162-167.
7. Potter L.R., Yoder A.R., Flora D.R., Antos L.K., Dickey D.M. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009, 191:341-366.
8. Fujii T., Komatsu Y., Yasoda A., Kondo E., Yoshioka T., Nambu T., et al. Circulating C-type natriuretic peptide (CNP) rescues chondrodysplastic CNP knockout mice from their impaired skeletal growth and early death. Endocrinology 2010, 151:4381-4388.
9. Chusho H., Tamura N., Ogawa Y., Yasoda A., Suda M., Miyazawa T., et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 2001, 98:4016-4021.
10. Kake T., Kitamura H., Adachi Y., Yoshioka T., Watanabe T., Matsushita H., et al. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice. Am J Physiol Endocrinol Metab 2009, 297:E1339-E1348.
11. Yasoda A., Komatsu Y., Chusho H., Miyazawa T., Ozasa A., Miura M., et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 2004, 10:80-86.
12. Komatsu Y., Chusho H., Tamura N., Yasoda A., Miyazawa T., Suda M., et al. Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice. JBone Miner Metab 2002, 20:331-336.
13. Miyazawa T., Ogawa Y., Chusho H., Yasoda A., Tamura N., Komatsu Y., et al. Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology 2002, 143:3604-3610.
14. Tsuji T., Kondo E., Yasoda A., Inamoto M., Kiyosu C., Nakao K., et al. Hypomorphic mutation in mouse Nppc gene causes retarded bone growth due to impaired endochondral ossification. Biochem Biophys Res Commun 2008, 376:186-190.
15. Kondo E., Yasoda A., Tsuji T., Fujii T., Miura M., Kanamoto N., et al. Skeletal analysis of the long bone abnormality (lbab/lbab) mouse, a novel chondrodysplastic C-type natriuretic peptide mutant. Calcif Tissue Int 2012, 90:307-318.
16. -/- mice. Peptides 2008, 29:1575-1581.
17. Tsuji T., Kunieda T. Aloss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. JBiol Chem 2005, 280:14288-14292.
18. Bukulmez H., Khan F., Bartels C.F., Murakami S., Ortiz-Lopez A., Sattar A., et al. Protective effects of C-type natriuretic peptide on linear growth and articular cartilage integrity in an inflammatory arthritis mouse model. Arthritis Rheum 2014, 66:78-89.
19. Bartels C.F., Bükülmez H., Padayatti P., Rhee D.K., van Ravenswaaij-Arts C., Pauli R.M., et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 2004, 75:27-34.
20. Olney R.C., Bükülmez H., Bartels C.F., Prickett T.C., Espiner E.A., Potter L.R., et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. JClin Endocrinol Metab 2006, 91:1229-1232.
21. Tassano E., Buttgereit J., Bader M., Lerone M., Divizia M.T., Bocciardi R., et al. Genotype-phenotype correlation of 2q37 deletions including gene associated with skeletal malformations. PLoS One 2013, 8:e66048.
22. Bocciardi R., Giorda R., Buttgereit J., Gimelli S., Divizia M.T., Beri S., et al. Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum Mutat 2007, 28:724-731.
23. Estrada K., Krawczak M., Schreiber S., van Duijn K., Stolk L., van Meurs J.B., et al. Agenome-wide association study of northwestern Europeans involves the C-type natriuretic peptide signaling pathway in the etiology of human height variation. Hum Mol Genet 2009, 18:3516-3524.
24. Olney R.C., Permuy J.W., Prickett T.C., Han J.C., Espiner E.A. Amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) predicts height velocity in healthy children. Clin Endocrinol (Oxf) 2012, 77:416-422.
25. Olney R.C., Prickett T.C., Yandle T.G., Espiner E.A., Han J.C., Mauras N. Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children: effects of puberty, testosterone, and growth hormone. JClin Endocrinol Metab 2007, 92:4294-4298.
26. Borrelli P., Fasanelli S., Marini R. Acromesomelic dwarfism in a child with an interesting family history. Pediatr Radiol 1983, 13:165-168.
27. Khan S., Ali R.H., Abbasi S., Nawaz M., Muhammad N., Ahmad W. Novel mutations in natriuretic peptide receptor-2 gene underlie acromesomelic dysplasia, type Maroteaux. BMC Med Genet 2012, 13:44.
28. Geister K.A., Brinkmeier M.L., Hsieh M., Faust S.M., Karolyi I.J., Perosky J.E., et al. Anovel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux type. Hum Mol Genet 2013, 22:345-357.
29. Matsukawa N., Grzesik W.J., Takahashi N., Pandey K.N., Pang S., Yamauchi M., et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 1999, 96:7403-7408.
30. Miura K., Namba N., Fujiwara M., Ohata Y., Ishida H., Kitaoka T., et al. An overgrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 gene. PLoS One 2012, 7:e42180.
31. Hagiwara H., Inoue A., Yamaguchi A., Yokose S., Furuya M., Tanaka S., et al. cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol 1996, 270(5 Pt 1):C1311-C1318.
32. Inoue A., Hayakawa T., Otsuka E., Kamiya A., Suzuki Y., Hirose S., et al. Correlation between induction of expression of biglycan and mineralization by C-type natriuretic peptide in osteoblastic cells. JBiochem 1999, 125:103-108.
33. Suda M., Tanaka K., Fukushima M., Natsui K., Yasoda A., Komatsu Y., et al. C-type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Biochem Biophys Res Commun 1996, 223:1-6.
34. Yeh L.C., Zavala M.C., Lee J.C. C-type natriuretic peptide enhances osteogenic protein-1-induced osteoblastic cell differentiation via Smad5 phosphorylation. JCell Biochem 2006, 97:494-500.
35. Agoston H., Khan S., James C.G., Gillespie J.R., Serra R., Stanton L.A., et al. C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and independent pathways. BMC Dev Biol 2007, 7:18.
36. Shaikh N., Russo L., Papaleo E., Giannoni P., De Gioia L., Nicotra F., et al. C-type natriuretic peptide: structural studies, fragment synthesis, and preliminary biological evaluation in human osteosarcoma cell lines. Biopolymers 2010, 94:213-219.
37. Lenz A., Bennett M., Skelton WPt, Vesely D.L. Vessel dilator and C-type natriuretic peptide enhance the proliferation of human osteoblasts. Pediatr Res 2010, 68:405-408.
38. Holliday L.S., Dean A.D., Greenwald J.E., Glucks S.L. C-type natriuretic peptide increases bone resorption in 1,25-dihydroxyvitamin D3-stimulated mouse bone marrow cultures. JBiol Chem 1995, 270:18983-18989.
39. Waldman S.D., Usmani Y., Tse M.Y., Pang S.C. Differential effects of natriuretic peptide stimulation on tissue-engineered cartilage. Tissue Eng Part A 2008, 14:441-448.
40. Peake N., Su N., Ramachandran M., Achan P., Salter D.M., Bader D.L., et al. Natriuretic peptide receptors regulate cytoprotective effects in a human exvivo 3D/bioreactor model. Arthritis Res Ther 2013, 15:R76.
41. Alan T., Tufan A.C. C-type natriuretic peptide regulation of limb mesenchymal chondrogenesis is accompanied by altered N-cadherin and collagen type X-related functions. JCell Biochem 2008, 105:227-235.
42. Suda M., Tanaka K., Yasoda A., Komatsu Y., Chusho H., Miura M., et al. C-type natriuretic peptide/guanylate cyclase B system in ATDC5 cells, a chondrogenic cell line. JBone Miner Metab 2002, 20:136-141.
43. Woods A., Khan S., Beier F. C-type natriuretic peptide regulates cellular condensation and glycosaminoglycan synthesis during chondrogenesis. Endocrinology 2007, 148(10):5030-5041.
44. Ramachandran M., Achan P., Salter D.M., Bader D.L., Chowdhury T.T. Biomechanical signals and the C-type natriuretic peptide counteract catabolic activities induced by IL-1beta in chondrocyte/agarose constructs. Arthritis Res Ther 2011, 13:R145.
45. Fujishige K., Kotera J., Yanaka N., Akatsuka H., Omori K. Alteration of cGMP metabolism during chondrogenic differentiation of chondroprogenitor-like EC cells, ATDC5. Biochim Biophys Acta 1999, 1452:219-227.
46. 1induced chondrogenic differentiation of mesenchymal stem cells. JMol Histol 2010, 41:247-258.
47. 1 induced chondrogenic differentiation of chicken bone marrow-derived mesenchymal stem cells. JMol Histol 2012, 43:497-508.
48. Ozasa A., Komatsu Y., Yasoda A., Miura M., Sakuma Y., Nakatsuru Y., et al. Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. Bone 2005, 36:1056-1064.
49. Krejci P., Masri B., Fontaine V., Mekikian P.B., Weis M., Prats H., et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. JCell Sci 2005, 118:5089-5100.
50. Khambata R.S., Panayiotou C.M., Hobbs A.J. Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide. Br J Pharmacol 2011, 164:584-597.
51. Suga S., Itoh H., Komatsu Y., Ogawa Y., Hama N., Yoshimasa T., et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 1993, 133:3038-3041.
52. Qian J.Y., Haruno A., Asada Y., Nishida T., Saito Y., Matsuda T., et al. Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res 2002, 91:1063-1069.
53. Prickett T.C., Hector-Taylor J., Olney R.C., Darlow B.A., Espiner E.A. Acute inflammation in young children inhibits C-type natriuretic peptide. Pediatr Res 2013, 74:191-195.
54. Kaneki H., Kurokawa M., Ide H. The receptor attributable to C-type natriuretic peptide-induced differentiation of osteoblasts is switched from type B- to type C-natriuretic peptide receptor with aging. JCell Biochem 2008, 103:753-764.
55. Prickett T.C., Olney R.C., Cameron V.A., Ellis M.J., Richards A.M., Espiner E.A. Impact of age, phenotype and cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an adult population. Clin Endocrinol (Oxf) 2013, 78:783-789.
56. Lorget F., Kaci N., Peng J., Benoist-Lasselin C., Mugniery E., Oppeneer T., et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet 2012, 91:1108-1114.
57. Yasoda A., Kitamura H., Fujii T., Kondo E., Murao N., Miura M., et al. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 2009, 150:3138-3144.
58. Evans C.H., Kraus V.B., Setton L.A. Progress in intra-articular therapy. Nat Rev Rheumatol 2014, 10:11-22.
59. Gerwin N., Hops C., Lucke A. Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev 2006, 58:226-242.
60. Réeff J., Gaignaux A., Goole J., De Vriese C., Amighi K. New sustained-release intraarticular gel formulations based on monolein for local treatment of arthritic diseases. Drug Dev Ind Pharm 2013, 39:1731-1741.
61. Kang M.L., Lm G. Drug delivery systems for intra-articular treatment of osteoarthritis. Exp Opin Drug Deliv 2014, 11:269-282.
62. Butoescu N., Jordan O., Doelker E. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance. Eur J Pharm Biopharm 2009, 73:205-218.
63. Kusumbe A.P., Ramasamy S.K., Adams R.H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 2014, 507:323-328.
64. Kusumbe A.P., Ramasamy S.K., Wang L., Adams R.H. Endothelial notch activity promotes angiogenesis and osteogenesis in bone. Nature 2014, 507:376-380.